The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...
The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...